HRP20191983T1 - Konstrukti protutijela za cdh19 i cd3 - Google Patents

Konstrukti protutijela za cdh19 i cd3 Download PDF

Info

Publication number
HRP20191983T1
HRP20191983T1 HRP20191983TT HRP20191983T HRP20191983T1 HR P20191983 T1 HRP20191983 T1 HR P20191983T1 HR P20191983T T HRP20191983T T HR P20191983TT HR P20191983 T HRP20191983 T HR P20191983T HR P20191983 T1 HRP20191983 T1 HR P20191983T1
Authority
HR
Croatia
Prior art keywords
seq
cdr
nos
antibody construct
construct according
Prior art date
Application number
HRP20191983TT
Other languages
English (en)
Inventor
Shouhua XIAO
Zheng PAN
Dineli Wickramasinghe
M. Shawn Jeffries
Chadwick Terence King
Brian Mingtung CHAN
Peter Kufer
Ralf Lutterbuese
Tobias Raum
Patrick Hoffmann
Doris Rau
Roman Kischel
Bryan LEMON
Holger Wesche
Original Assignee
Amgen Research (Munich) Gmbh
Amgen, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50137614&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20191983(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Research (Munich) Gmbh, Amgen, Inc filed Critical Amgen Research (Munich) Gmbh
Publication of HRP20191983T1 publication Critical patent/HRP20191983T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Claims (15)

1. Izolirani multispecifični konstrukt protutijela koji sadrži prvu ljudsku vezujuću domenu koja se može vezati za ljudski CDH19 na površini ciljne stanice i drugu domenu koja se može vezati za ljudski CD3 na površini T stanice, naznačen time što prva vezujuća domena sadrži VH regiju koja sadrži CDR-H1, CDR-H2 i CDR-H3 i VL regiju koja sadrži CDR-L1, CDR-L2 i CDR-L3 odabrane iz skupine koja se sastoji od: CDR-H1 kako je prikazano u SEQ ID NO: 4, CDR-H2 kako je prikazano u SEQ ID NO: 5, CDR-H3 kako je prikazano u SEQ ID NO: 6, CDR-L1 kako je prikazano u SEQ ID NO: 172, CDR-L2 kako je prikazano u SEQ ID NO: 173 i CDR-L3 kako je prikazano u SEQ ID NO: 174; CDR-H1 kako je prikazano u SEQ ID NO: 10, CDR-H2 kako je prikazano u SEQ ID NO: 11, CDR-H3 kako je prikazano u SEQ ID NO: 12, CDR-L1 kako je prikazano u SEQ ID NO: 178, CDR-L2 kako je prikazano u SEQ ID NO: 179 i CDR-L3 kako je prikazano u SEQ ID NO: 180; CDR-H1 kako je prikazano u SEQ ID NO: 28, CDR-H2 kako je prikazano u SEQ ID NO: 29, CDR-H3 kako je prikazano u SEQ ID NO: 30, CDR-L1 kako je prikazano u SEQ ID NO: 196, CDR-L2 kako je prikazano u SEQ ID NO: 197 i CDR-L3 kako je prikazano u SEQ ID NO: 198; CDR-H1 kako je prikazano u SEQ ID NO: 34, CDR-H2 kako je prikazano u SEQ ID NO: 35, CDR-H3 kako je prikazano u SEQ ID NO: 36, CDR-L1 kako je prikazano u SEQ ID NO: 202, CDR-L2 kako je prikazano u SEQ ID NO: 203 i CDR-L3 kako je prikazano u SEQ ID NO: 204; CDR-H1 kako je prikazano u SEQ ID NO: 46, CDR-H2 kako je prikazano u SEQ ID NO: 47, CDR-H3 kako je prikazano u SEQ ID NO: 48, CDR-L1 kako je prikazano u SEQ ID NO: 214, CDR-L2 kako je prikazano u SEQ ID NO: 215 i CDR-L3 kako je prikazano u SEQ ID NO: 216; CDR-H1 kako je prikazano u SEQ ID NO: 58, CDR-H2 kako je prikazano u SEQ ID NO: 59, CDR-H3 kako je prikazano u SEQ ID NO: 60, CDR-L1 kako je prikazano u SEQ ID NO: 226, CDR-L2 kako je prikazano u SEQ ID NO: 227 i CDR-L3 kako je prikazano u SEQ ID NO: 228; CDR-H1 kako je prikazano u SEQ ID NO: 64, CDR-H2 kako je prikazano u SEQ ID NO: 65, CDR-H3 kako je prikazano u SEQ ID NO: 66, CDR-L1 kako je prikazano u SEQ ID NO: 232, CDR-L2 kako je prikazano u SEQ ID NO: 233 i CDR-L3 kako je prikazano u SEQ ID NO: 234; CDR-H1 kako je prikazano u SEQ ID NO: 70, CDR-H2 kako je prikazano u SEQ ID NO: 71, CDR-H3 kako je prikazano u SEQ ID NO: 72, CDR-L1 kako je prikazano u SEQ ID NO: 238, CDR-L2 kako je prikazano u SEQ ID NO: 239 i CDR-L3 kako je prikazano u SEQ ID NO: 240; CDR-H1 kako je prikazano u SEQ ID NO: 160, CDR-H2 kako je prikazano u SEQ ID NO: 161, CDR-H3 kako je prikazano u SEQ ID NO: 162, CDR-L1 kako je prikazano u SEQ ID NO: 328, CDR-L2 kako je prikazano u SEQ ID NO: 329 i CDR-L3 kako je prikazano u SEQ ID NO: 330; CDR-H1 kako je prikazano u SEQ ID NO: 46, CDR-H2 kako je prikazano u SEQ ID NO: 47, CDR-H3 kako je prikazano u SEQ ID NO: 48, CDR-L1 kako je prikazano u SEQ ID NO: 924, CDR-L2 kako je prikazano u SEQ ID NO: 215 i CDR-L3 kako je prikazano u SEQ ID NO: 216; CDR-H1 kako je prikazano u SEQ ID NO: 46, CDR-H2 kako je prikazano u SEQ ID NO: 47, CDR-H3 kako je prikazano u SEQ ID NO: 902, CDR-L1 kako je prikazano u SEQ ID NO: 924, CDR-L2 kako je prikazano u SEQ ID NO: 215 i CDR-L3 kako je prikazano u SEQ ID NO: 216; CDR-H1 kako je prikazano u SEQ ID NO: 46, CDR-H2 kako je prikazano u SEQ ID NO: 47, CDR-H3 kako je prikazano u SEQ ID NO: 903, CDR-L1 kako je prikazano u SEQ ID NO: 924, CDR-L2 kako je prikazano u SEQ ID NO: 215 i CDR-L3 kako je prikazano u SEQ ID NO: 216; CDR-H1 kako je prikazano u SEQ ID NO: 46, CDR-H2 kako je prikazano u SEQ ID NO: 47, CDR-H3 kako je prikazano u SEQ ID NO: 48, CDR-L1 kako je prikazano u SEQ ID NO: 925, CDR-L2 kako je prikazano u SEQ ID NO: 215 i CDR-L3 kako je prikazano u SEQ ID NO: 216; CDR-H1 kako je prikazano u SEQ ID NO: 70, CDR-H2 kako je prikazano u SEQ ID NO: 907, CDR-H3 kako je prikazano u SEQ ID NO: 72, CDR-L1 kako je prikazano u SEQ ID NO: 238, CDR-L2 kako je prikazano u SEQ ID NO: 239 i CDR-L3 kako je prikazano u SEQ ID NO: 240; CDR-H1 kako je prikazano u SEQ ID NO: 70, CDR-H2 kako je prikazano u SEQ ID NO: 907, CDR-H3 kako je prikazano u SEQ ID NO: 908, CDR-L1 kako je prikazano u SEQ ID NO: 238, CDR-L2 kako je prikazano u SEQ ID NO: 239 i CDR-L3 kako je prikazano u SEQ ID NO: 240; CDR-H1 kako je prikazano u SEQ ID NO: 28, CDR-H2 kako je prikazano u SEQ ID NO: 901, CDR-H3 kako je prikazano u SEQ ID NO: 30, CDR-L1 kako je prikazano u SEQ ID NO: 922, CDR-L2 kako je prikazano u SEQ ID NO: 197 i CDR-L3 kako je prikazano u SEQ ID NO: 923; CDR-H1 kako je prikazano u SEQ ID NO: 58, CDR-H2 kako je prikazano u SEQ ID NO: 905, CDR-H3 kako je prikazano u SEQ ID NO: 906, CDR-L1 kako je prikazano u SEQ ID NO: 226, CDR-L2 kako je prikazano u SEQ ID NO: 227 i CDR-L3 kako je prikazano u SEQ ID NO: 228; CDR-H1 kako je prikazano u SEQ ID NO: 58, CDR-H2 kako je prikazano u SEQ ID NO: 905, CDR-H3 kako je prikazano u SEQ ID NO: 60, CDR-L1 kako je prikazano u SEQ ID NO: 226, CDR-L2 kako je prikazano u SEQ ID NO: 227 i CDR-L3 kako je prikazano u SEQ ID NO: 228; CDR-H1 kako je prikazano u SEQ ID NO: 160, CDR-H2 kako je prikazano u SEQ ID NO: 161, CDR-H3 kako je prikazano u SEQ ID NO: 162, CDR-L1 kako je prikazano u SEQ ID NO: 939, CDR-L2 kako je prikazano u SEQ ID NO: 329 i CDR-L3 kako je prikazano u SEQ ID NO: 330; CDR-H1 kako je prikazano u SEQ ID NO: 160, CDR-H2 kako je prikazano u SEQ ID NO: 921, CDR-H3 kako je prikazano u SEQ ID NO: 162, CDR-L1 kako je prikazano u SEQ ID NO: 939, CDR-L2 kako je prikazano u SEQ ID NO: 329 i CDR-L3 kako je prikazano u SEQ ID NO: 940; CDR-H1 kako je prikazano u SEQ ID NO: 160, CDR-H2 kako je prikazano u SEQ ID NO: 161, CDR-H3 kako je prikazano u SEQ ID NO: 162, CDR-L1 kako je prikazano u SEQ ID NO: 941, CDR-L2 kako je prikazano u SEQ ID NO: 329 i CDR-L3 kako je prikazano u SEQ ID NO: 330; CDR-H1 kako je prikazano u SEQ ID NO: 28, CDR-H2 kako je prikazano u SEQ ID NO: 29, CDR-H3 kako je prikazano u SEQ ID NO: 30, CDR-L1 kako je prikazano u SEQ ID NO: 196, CDR-L2 kako je prikazano u SEQ ID NO: 197 i CDR-L3 kako je prikazano u SEQ ID NO: 923; CDR-H1 kako je prikazano u SEQ ID NO: 28, CDR-H2 kako je prikazano u SEQ ID NO: 29, CDR-H3 kako je prikazano u SEQ ID NO: 30, CDR-L1 kako je prikazano u SEQ ID NO: 922, CDR-L2 kako je prikazano u SEQ ID NO: 197 i CDR-L3 kako je prikazano u SEQ ID NO: 923; CDR-H1 kako je prikazano u SEQ ID NO: 28, CDR-H2 kako je prikazano u SEQ ID NO: 901, CDR-H3 kako je prikazano u SEQ ID NO: 30, CDR-L1 kako je prikazano u SEQ ID NO: 922, CDR-L2 kako je prikazano u SEQ ID NO: 197 i CDR-L3 kako je prikazano u SEQ ID NO: 923; CDR-H1 kako je prikazano u SEQ ID NO: 28, CDR-H2 kako je prikazano u SEQ ID NO: 29, CDR-H3 kako je prikazano u SEQ ID NO: 30, CDR-L1 kako je prikazano u SEQ ID NO: 939, CDR-L2 kako je prikazano u SEQ ID NO: 329 i CDR-L3 kako je prikazano u SEQ ID NO: 330; CDR-H1 kako je prikazano u SEQ ID NO: 970, CDR-H2 kako je prikazano u SEQ ID NO: 971, CDR-H3 kako je prikazano u SEQ ID NO: 972, CDR-L1 kako je prikazano u SEQ ID NO: 973, CDR-L2 kako je prikazano u SEQ ID NO: 974 i CDR-L3 kako je prikazano u SEQ ID NO: 975; CDR-H1 kako je prikazano u SEQ ID NO: 1061, CDR-H2 kako je prikazano u SEQ ID NO: 1062, CDR-H3 kako je prikazano u SEQ ID NO: 1063, CDR-L1 kako je prikazano u SEQ ID NO: 1064, CDR-L2 kako je prikazano u SEQ ID NO: 1065 i CDR-L3 kako je prikazano u SEQ ID NO: 1066; CDR-H1 kako je prikazano u SEQ ID NO: 1139, CDR-H2 kako je prikazano u SEQ ID NO: 1140, CDR-H3 kako je prikazano u SEQ ID NO: 1141, CDR-L1 kako je prikazano u SEQ ID NO: 1142, CDR-L2 kako je prikazano u SEQ ID NO: 1143 i CDR-L3 kako je prikazano u SEQ ID NO: 1144; CDR-H1 kako je prikazano u SEQ ID NO: 1152, CDR-H2 kako je prikazano u SEQ ID NO: 1153, CDR-H3 kako je prikazano u SEQ ID NO: 1154, CDR-L1 kako je prikazano u SEQ ID NO: 1155, CDR-L2 kako je prikazano u SEQ ID NO: 1156 i CDR-L3 kako je prikazano u SEQ ID NO: 1157; CDR-H1 kako je prikazano u SEQ ID NO: 1178, CDR-H2 kako je prikazano u SEQ ID NO: 1179, CDR-H3 kako je prikazano u SEQ ID NO: 1180, CDR-L1 kako je prikazano u SEQ ID NO: 1181, CDR-L2 kako je prikazano u SEQ ID NO: 1182 i CDR-L3 kako je prikazano u SEQ ID NO: 1183; CDR-H1 kako je prikazano u SEQ ID NO: 1191, CDR-H2 kako je prikazano u SEQ ID NO: 1192, CDR-H3 kako je prikazano u SEQ ID NO: 1193, CDR-L1 kako je prikazano u SEQ ID NO: 1194, CDR-L2 kako je prikazano u SEQ ID NO: 1195 i CDR-L3 kako je prikazano u SEQ ID NO: 1196; CDR-H1 kako je prikazano u SEQ ID NO: 1204, CDR-H2 kako je prikazano u SEQ ID NO: 1205, CDR-H3 kako je prikazano u SEQ ID NO: 1206, CDR-L1 kako je prikazano u SEQ ID NO: 1207, CDR-L2 kako je prikazano u SEQ ID NO: 1208 i CDR-L3 kako je prikazano u SEQ ID NO: 1209; CDR-H1 kako je prikazano u SEQ ID NO: 1217, CDR-H2 kako je prikazano u SEQ ID NO: 1218, CDR-H3 kako je prikazano u SEQ ID NO: 1219, CDR-L1 kako je prikazano u SEQ ID NO: 1220, CDR-L2 kako je prikazano u SEQ ID NO: 1221 i CDR-L3 kako je prikazano u SEQ ID NO: 1222; CDR-H1 kako je prikazano u SEQ ID NO: 1230, CDR-H2 kako je prikazano u SEQ ID NO: 1231, CDR-H3 kako je prikazano u SEQ ID NO: 1232, CDR-L1 kako je prikazano u SEQ ID NO: 1233, CDR-L2 kako je prikazano u SEQ ID NO: 1234 i CDR-L3 kako je prikazano u SEQ ID NO: 1235; CDR-H1 kako je prikazano u SEQ ID NO: 1308, CDR-H2 kako je prikazano u SEQ ID NO: 1309, CDR-H3 kako je prikazano u SEQ ID NO: 1310, CDR-L1 kako je prikazano u SEQ ID NO: 1311, CDR-L2 kako je prikazano u SEQ ID NO: 1312 i CDR-L3 kako je prikazano u SEQ ID NO: 1313; CDR-H1 kako je prikazano u SEQ ID NO: 1321, CDR-H2 kako je prikazano u SEQ ID NO: 1322, CDR-H3 kako je prikazano u SEQ ID NO: 1323, CDR-L1 kako je prikazano u SEQ ID NO: 1324, CDR-L2 kako je prikazano u SEQ ID NO: 1325 i CDR-L3 kako je prikazano u SEQ ID NO: 1326; CDR-H1 kako je prikazano u SEQ ID NO: 1373, CDR-H2 kako je prikazano u SEQ ID NO: 1374, CDR-H3 kako je prikazano u SEQ ID NO: 1375, CDR-L1 kako je prikazano u SEQ ID NO: 1376, CDR-L2 kako je prikazano u SEQ ID NO: 1377 i CDR-L3 kako je prikazano u SEQ ID NO: 1378; CDR-H1 kako je prikazano u SEQ ID NO: 1386, CDR-H2 kako je prikazano u SEQ ID NO: 1387, CDR-H3 kako je prikazano u SEQ ID NO: 1388, CDR-L1 kako je prikazano u SEQ ID NO: 1389, CDR-L2 kako je prikazano u SEQ ID NO: 1390 i CDR-L3 kako je prikazano u SEQ ID NO: 1391; CDR-H1 kako je prikazano u SEQ ID NO: 1399, CDR-H2 kako je prikazano u SEQ ID NO: 1400, CDR-H3 kako je prikazano u SEQ ID NO: 1401, CDR-L1 kako je prikazano u SEQ ID NO: 1402, CDR-L2 kako je prikazano u SEQ ID NO: 1403 i CDR-L3 kako je prikazano u SEQ ID NO: 1404; CDR-H1 kako je prikazano u SEQ ID NO: 1412, CDR-H2 kako je prikazano u SEQ ID NO: 1413, CDR-H3 kako je prikazano u SEQ ID NO: 1414, CDR-L1 kako je prikazano u SEQ ID NO: 1415, CDR-L2 kako je prikazano u SEQ ID NO: 1416 i CDR-L3 kako je prikazano u SEQ ID NO: 1417; CDR-H1 kako je prikazano u SEQ ID NO: 1777, CDR-H2 kako je prikazano u SEQ ID NO: 1778, CDR-H3 kako je prikazano u SEQ ID NO: 1779, CDR-L1 kako je prikazano u SEQ ID NO: 1780, CDR-L2 kako je prikazano u SEQ ID NO: 1781 i CDR-L3 kako je prikazano u SEQ ID NO: 1782; CDR-H1 kako je prikazano u SEQ ID NO: 1790, CDR-H2 kako je prikazano u SEQ ID NO: 1791, CDR-H3 kako je prikazano u SEQ ID NO: 1792, CDR-L1 kako je prikazano u SEQ ID NO: 1793, CDR-L2 kako je prikazano u SEQ ID NO: 1794 i CDR-L3 kako je prikazano u SEQ ID NO: 1795; CDR-H1 kako je prikazano u SEQ ID NO: 1803, CDR-H2 kako je prikazano u SEQ ID NO: 1804, CDR-H3 kako je prikazano u SEQ ID NO: 1805, CDR-L1 kako je prikazano u SEQ ID NO: 1806, CDR-L2 kako je prikazano u SEQ ID NO: 1807 i CDR-L3 kako je prikazano u SEQ ID NO: 1808; CDR-H1 kako je prikazano u SEQ ID NO: 1816, CDR-H2 kako je prikazano u SEQ ID NO: 1817, CDR-H3 kako je prikazano u SEQ ID NO: 1818, CDR-L1 kako je prikazano u SEQ ID NO: 1819, CDR-L2 kako je prikazano u SEQ ID NO: 1820 i CDR-L3 kako je prikazano u SEQ ID NO: 1821; CDR-H1 kako je prikazano u SEQ ID NO: 1829, CDR-H2 kako je prikazano u SEQ ID NO: 1830, CDR-H3 kako je prikazano u SEQ ID NO: 1831, CDR-L1 kako je prikazano u SEQ ID NO: 1832, CDR-L2 kako je prikazano u SEQ ID NO: 1833 i CDR-L3 kako je prikazano u SEQ ID NO: 1834; CDR-H1 kako je prikazano u SEQ ID NO: 1842, CDR-H2 kako je prikazano u SEQ ID NO: 1843, CDR-H3 kako je prikazano u SEQ ID NO: 1844, CDR-L1 kako je prikazano u SEQ ID NO: 1845, CDR-L2 kako je prikazano u SEQ ID NO: 1846 i CDR-L3 kako je prikazano u SEQ ID NO: 1847; CDR-H1 kako je prikazano u SEQ ID NO: 1855, CDR-H2 kako je prikazano u SEQ ID NO: 1856, CDR-H3 kako je prikazano u SEQ ID NO: 1857, CDR-L1 kako je prikazano u SEQ ID NO: 1858, CDR-L2 kako je prikazano u SEQ ID NO: 1859 i CDR-L3 kako je prikazano u SEQ ID NO: 1860; CDR-H1 kako je prikazano u SEQ ID NO: 1868, CDR-H2 kako je prikazano u SEQ ID NO: 1869, CDR-H3 kako je prikazano u SEQ ID NO: 1870, CDR-L1 kako je prikazano u SEQ ID NO: 1871, CDR-L2 kako je prikazano u SEQ ID NO: 1872 i CDR-L3 kako je prikazano u SEQ ID NO: 1873; CDR-H1 kako je prikazano u SEQ ID NO: 1881, CDR-H2 kako je prikazano u SEQ ID NO: 1882, CDR-H3 kako je prikazano u SEQ ID NO: 1883, CDR-L1 kako je prikazano u SEQ ID NO: 1884, CDR-L2 kako je prikazano u SEQ ID NO: 1885 i CDR-L3 kako je prikazano u SEQ ID NO: 1886; CDR-H1 kako je prikazano u SEQ ID NO: 2063, CDR-H2 kako je prikazano u SEQ ID NO: 2064, CDR-H3 kako je prikazano u SEQ ID NO: 2065, CDR-L1 kako je prikazano u SEQ ID NO: 2066, CDR-L2 kako je prikazano u SEQ ID NO: 2067 i CDR-L3 kako je prikazano u SEQ ID NO: 2068; CDR-H1 kako je prikazano u SEQ ID NO: 2076, CDR-H2 kako je prikazano u SEQ ID NO: 2077, CDR-H3 kako je prikazano u SEQ ID NO: 2078, CDR-L1 kako je prikazano u SEQ ID NO: 2079, CDR-L2 kako je prikazano u SEQ ID NO: 2080 i CDR-L3 kako je prikazano u SEQ ID NO: 2081; CDR-H1 kako je prikazano u SEQ ID NO: 2089, CDR-H2 kako je prikazano u SEQ ID NO: 2090, CDR-H3 kako je prikazano u SEQ ID NO: 2091, CDR-L1 kako je prikazano u SEQ ID NO: 2092, CDR-L2 kako je prikazano u SEQ ID NO: 2093 i CDR-L3 kako je prikazano u SEQ ID NO: 2096; CDR-H1 kako je prikazano u SEQ ID NO: 2102, CDR-H2 kako je prikazano u SEQ ID NO: 2103, CDR-H3 kako je prikazano u SEQ ID NO: 2104, CDR-L1 kako je prikazano u SEQ ID NO: 2105, CDR-L2 kako je prikazano u SEQ ID NO: 2106 i CDR-L3 kako je prikazano u SEQ ID NO: 2107; CDR-H1 kako je prikazano u SEQ ID NO: 2115, CDR-H2 kako je prikazano u SEQ ID NO: 2116, CDR-H3 kako je prikazano u SEQ ID NO: 2117, CDR-L1 kako je prikazano u SEQ ID NO: 2118, CDR-L2 kako je prikazano u SEQ ID NO: 2119 i CDR-L3 kako je prikazano u SEQ ID NO: 2120; CDR-H1 kako je prikazano u SEQ ID NO: 2128, CDR-H2 kako je prikazano u SEQ ID NO: 2129, CDR-H3 kako je prikazano u SEQ ID NO: 2130, CDR-L1 kako je prikazano u SEQ ID NO: 2131, CDR-L2 kako je prikazano u SEQ ID NO: 2132 i CDR-L3 kako je prikazano u SEQ ID NO: 2133; CDR-H1 kako je prikazano u SEQ ID NO: 2141, CDR-H2 kako je prikazano u SEQ ID NO: 2142, CDR-H3 kako je prikazano u SEQ ID NO: 2143, CDR-L1 kako je prikazano u SEQ ID NO: 2144, CDR-L2 kako je prikazano u SEQ ID NO: 2145 i CDR-L3 kako je prikazano u SEQ ID NO: 2146; CDR-H1 kako je prikazano u SEQ ID NO: 2154, CDR-H2 kako je prikazano u SEQ ID NO: 2155, CDR-H3 kako je prikazano u SEQ ID NO: 2156, CDR-L1 kako je prikazano u SEQ ID NO: 2157, CDR-L2 kako je prikazano u SEQ ID NO: 2158 i CDR-L3 kako je prikazano u SEQ ID NO: 2159; CDR-H1 kako je prikazano u SEQ ID NO: 2180, CDR-H2 kako je prikazano u SEQ ID NO: 2181, CDR-H3 kako je prikazano u SEQ ID NO: 2182, CDR-L1 kako je prikazano u SEQ ID NO: 2183, CDR-L2 kako je prikazano u SEQ ID NO: 2184 i CDR-L3 kako je prikazano u SEQ ID NO: 2185; CDR-H1 kako je prikazano u SEQ ID NO: 2193, CDR-H2 kako je prikazano u SEQ ID NO: 2194, CDR-H3 kako je prikazano u SEQ ID NO: 2195, CDR-L1 kako je prikazano u SEQ ID NO: 2196, CDR-L2 kako je prikazano u SEQ ID NO: 2197 i CDR-L3 kako je prikazano u SEQ ID NO: 2198; i CDR-H1 kako je prikazano u SEQ ID NO: 2206, CDR-H2 kako je prikazano u SEQ ID NO: 2207, CDR-H3 kako je prikazano u SEQ ID NO: 2208, CDR-L1 kako je prikazano u SEQ ID NO: 2209, CDR-L2 kako je prikazano u SEQ ID NO: 2210 i CDR-L3 kako je prikazano u SEQ ID NO: 2211.
2. Konstrukt protutijela prema patentnom zahtjevu 1, naznačen time što prva vezujuća domena sadrži VH regiju odabranu iz skupine koja sadrži VH regije kako je prikazano u SEQ ID NO: 352, SEQ ID NO: 360, SEQ ID NO: 388, SEQ ID NO: 386, SEQ ID NO: 340, SEQ ID NO: 346, SEQ ID NO: 374, SEQ ID NO: 348, SEQ ID NO: 390, SEQ ID NO: 463, SEQ ID NO: 464, SEQ ID NO: 465, SEQ ID NO: 466, SEQ ID NO: 467, SEQ ID NO: 468, SEQ ID NO: 469, SEQ ID NO: 470, SEQ ID NO: 471, SEQ ID NO: 472, SEQ ID NO: 473, SEQ ID NO: 474, SEQ ID NO: 475, SEQ ID NO: 488, SEQ ID NO: 489, SEQ ID NO: 490, SEQ ID NO: 491, SEQ ID NO: 513, SEQ ID NO: 514, SEQ ID NO: 515, SEQ ID NO: 516, SEQ ID NO: 540, SEQ ID NO: 541, SEQ ID NO: 542, SEQ ID NO: 543, SEQ ID NO: 977, SEQ ID NO: 1068, SEQ ID NO: 1146, SEQ ID NO: 1159, SEQ ID NO: 1185, SEQ ID NO: 1198, SEQ ID NO: 1211, SEQ ID NO: 1224, SEQ ID NO: 1237, SEQ ID NO: 1315, SEQ ID NO: 1328, SEQ ID NO: 1380, SEQ ID NO: 1393, SEQ ID NO: 1406, SEQ ID NO: 1419, SEQ ID NO: 1469, SEQ ID NO: 1478, SEQ ID NO: 1485, SEQ ID NO: 1494, SEQ ID NO: 1501, SEQ ID NO: 1508, SEQ ID NO: 1519, SEQ ID NO: 1526, SEQ ID NO: 1533, SEQ ID NO: 1542, SEQ ID NO: 1549, SEQ ID NO: 1558, SEQ ID NO: 1565, SEQ ID NO: 1784, SEQ ID NO: 1797, SEQ ID NO: 1810, SEQ ID NO: 1823, SEQ ID NO: 1836, SEQ ID NO: 1849, SEQ ID NO: 1862, SEQ ID NO: 1875, SEQ ID NO: 1888, SEQ ID NO: 2070, SEQ ID NO: 2083, SEQ ID NO: 2096, SEQ ID NO: 2109, SEQ ID NO: 2122, SEQ ID NO: 2135, SEQ ID NO: 2148, SEQ ID NO: 2161, SEQ ID NO: 2187, SEQ ID NO: 2200, i SEQ ID NO: 2213.
3. Konstrukt protutijela prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time što prva vezujuća domena sadrži VL regiju odabranu iz skupine koja sadrži VL regije kako je prikazano u SEQ ID NO: 408, SEQ ID NO: 416, SEQ ID NO: 444, SEQ ID NO: 442, SEQ ID NO: 396, SEQ ID NO: 402, SEQ ID NO: 430, SEQ ID NO: 404, SEQ ID NO: 446, SEQ ID NO: 558, SEQ ID NO: 559, SEQ ID NO: 560, SEQ ID NO: 561, SEQ ID NO: 562, SEQ ID NO: 563, SEQ ID NO: 564, SEQ ID NO: 565, SEQ ID NO: 566, SEQ ID NO: 567, SEQ ID NO: 568, SEQ ID NO: 569, SEQ ID NO: 570, SEQ ID NO: 583, SEQ ID NO: 584, SEQ ID NO: 585, SEQ ID NO: 586, SEQ ID NO: 608, SEQ ID NO: 609, SEQ ID NO: 610, SEQ ID NO: 611, SEQ ID NO: 635, SEQ ID NO: 636, SEQ ID NO: 637, SEQ ID NO: 638, SEQ ID NO: 979, SEQ ID NO: 1070, SEQ ID NO: 1148, SEQ ID NO: 1161, SEQ ID NO: 1187, SEQ ID NO: 1200, SEQ ID NO: 1213, SEQ ID NO: 1226, SEQ ID NO: 1239, SEQ ID NO: 1317, SEQ ID NO: 1330, SEQ ID NO: 1382, SEQ ID NO: 1395, SEQ ID NO: 1408, SEQ ID NO: 1421, SEQ ID NO: 1471, SEQ ID NO: 1480, SEQ ID NO: 1487, SEQ ID NO: 1496, SEQ ID NO: 1503, SEQ ID NO: 1510, SEQ ID NO: 1521, SEQ ID NO: 1528, SEQ ID NO: 1535, SEQ ID NO: 1544, SEQ ID NO: 1551, SEQ ID NO: 1560, SEQ ID NO: 1567, SEQ ID NO: 1786, SEQ ID NO: 1799, SEQ ID NO: 1812, SEQ ID NO: 1825, SEQ ID NO: 1838, SEQ ID NO: 1851, SEQ ID NO: 1864, SEQ ID NO: 1877, SEQ ID NO: 1890, SEQ ID NO: 2072, SEQ ID NO: 2085, SEQ ID NO: 2098, SEQ ID NO: 2111, SEQ ID NO: 2124, SEQ ID NO: 2137, SEQ ID NO: 2150, SEQ ID NO: 2163, SEQ ID NO: 2189, SEQ ID NO: 2202, i SEQ ID NO: 2215.
4. Konstrukt protutijela prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time što prva vezujuća domena sadrži VH regiju i VL regiju odabranu iz skupine koja sadrži: parove VH regije i VL regije kako je prikazano u SEQ ID NOs: 352+408, SEQ ID NOs: 360+416, SEQ ID NOs: 388+444, SEQ ID NOs: 386+442, SEQ ID NOs: 340+396, SEQ ID NOs: 346+402, SEQ ID NOs: 374+430, SEQ ID NOs: 348+404, SEQ ID NOs: 390+446, SEQ ID NOs: 463+558, SEQ ID NOs: 464+559, SEQ ID NOs: 465+560, SEQ ID NOs: 466+561, SEQ ID NOs: 467+562, SEQ ID NOs: 468+563, SEQ ID NOs: 469+564, SEQ ID NOs: 470+565, SEQ ID NOs: 471+566, SEQ ID NOs: 472+567, SEQ ID NOs: 473+568, SEQ ID NOs: 474+569, SEQ ID NOs: 475+570, SEQ ID NOs: 488+583, SEQ ID NOs: 489+584, SEQ ID NOs: 490+585, SEQ ID NOs: 491+586, SEQ ID NOs: 513+608, SEQ ID NOs: 514+609, SEQ ID NOs: 515+610, SEQ ID NOs: 516+611, SEQ ID NOs: 540+635, SEQ ID NOs: 541+636, SEQ ID NOs: 542+637, SEQ ID NOs: 543+638, SEQ ID NOs: 977+979, SEQ ID NOs: 1068+1070, SEQ ID NOs: 1146+1148, SEQ ID NOs: 1159+1161, SEQ ID NOs: 1185+1187, SEQ ID NOs: 1198+1200, SEQ ID NOs: 1211+1213, SEQ ID NOs: 1224+1226, SEQ ID NOs: 1237+1239, SEQ ID NOs: 1315+1317, SEQ ID NOs: 1328+1330, SEQ ID NOs: 1380+1382 SEQ ID NOs: 1393+1395, SEQ ID NOs: 1406+1408, SEQ ID NOs: 1419+1421, SEQ ID NOs: 1469+1471, SEQ ID NOs: 1478+1480, SEQ ID NOs: 1485+1487, SEQ ID NOs: 1494+1496, SEQ ID NOs: 1501+1503, SEQ ID NOs: 1508+1510, SEQ ID NOs: 1519+1521, SEQ ID NOs: 1526+1528, SEQ ID NOs: 1533+1535, SEQ ID NOs: 1542+1544, SEQ ID NOs: 1549+1551, SEQ ID NOs: 1558+1560, SEQ ID NOs: 1565+1567, SEQ ID NOs: 1784+1786, SEQ ID NOs: 1797+1799, SEQ ID NOs: 1810+1812, SEQ ID NOs: 1823+1825, SEQ ID NOs: 1836+1838, SEQ ID NOs: 1849+1851, SEQ ID NOs: 1862+1864, SEQ ID NOs: 1875+1877, SEQ ID NOs: 1888+1890, SEQ ID NOs: 2070+2072, SEQ ID NOs: 2083+2085, SEQ ID NOs: 2096+2098, SEQ ID NOs: 2109+2111, SEQ ID NOs: 2122+2124, SEQ ID NOs: 2135+2137, SEQ ID NOs: 2148+2150, SEQ ID NOs: 2161+2163, SEQ ID NOs: 2187+2189, SEQ ID NOs: 2200+2202, i SEQ ID NOs: 2213+2215.
5. Konstrukt protutijela prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time što je konstrukt protutijela u formatu odabranom iz skupine koja sadrži (scFv)2, scFv s jedno domenskim mAb, diatijela i njihove oligomere.
6. Konstrukt protutijela prema patentnom zahtjevu 5, naznačen time što prva vezujuća domena sadrži sekvencu aminokiseline odabranu iz skupine koja sadrži kako je prikazano u SEQ ID NO: 981, SEQ ID NO: 1072, SEQ ID NO: 1150, SEQ ID NO: 1163, SEQ ID NO: 1189, SEQ ID NO: 1202, SEQ ID NO: 1215, SEQ ID NO: 1228, SEQ ID NO: 1241, SEQ ID NO: 1319, SEQ ID NO: 1332, SEQ ID NO: 1384, SEQ ID NO: 1397, SEQ ID NO: 1410, SEQ ID NO: 1423, SEQ ID NO: 1473, SEQ ID NO: 1482, SEQ ID NO: 1489, SEQ ID NO: 1498, SEQ ID NO: 1505, SEQ ID NO: 1512, SEQ ID NO: 1523, SEQ ID NO: 1530, SEQ ID NO: 1537, SEQ ID NO: 1546, SEQ ID NO: 1553, SEQ ID NO: 1562, SEQ ID NO: 1569, SEQ ID NO: 1788, SEQ ID NO: 1801, SEQ ID NO: 1814, SEQ ID NO: 1827, SEQ ID NO: 1840, SEQ ID NO: 1853, SEQ ID NO: 1866, SEQ ID NO: 1879, SEQ ID NO: 1892, SEQ ID NO: 2074, SEQ ID NO: 2087, SEQ ID NO: 2100, SEQ ID NO: 2113, SEQ ID NO: 2126, SEQ ID NO: 2139, SEQ ID NO: 2152, SEQ ID NO: 2165, SEQ ID NO: 2191, SEQ ID NO: 2204, i SEQ ID NO: 2217.
7. Konstrukt protutijela prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time što se druga vezujuća domena može vezati na ljudski i Callithrix jacchus, Saguinus Edip ili Saimiri sciureus CD3 ipsilon.
8. Konstrukt protutijela prema patentnom zahtjevu 7, naznačen time što ima sekvencu aminokiseline odabranu iz skupine koja sadrži kako je prikazano u SEQ ID NO: 982, SEQ ID NO: 1073, SEQ ID NO: 1151, SEQ ID NO: 1164, SEQ ID NO: 1190, SEQ ID NO: 1203, SEQ ID NO: 1216, SEQ ID NO: 1229, SEQ ID NO: 1242, SEQ ID NO: 1320, SEQ ID NO: 1333, SEQ ID NO: 1385, SEQ ID NO: 1398, SEQ ID NO: 1411, SEQ ID NO: 1424, SEQ ID NO: 1474, SEQ ID NO: 1475, SEQ ID NO: 1476, SEQ ID NO: 1483, SEQ ID NO: 1490, SEQ ID NO: 1491, SEQ ID NO: 1492, SEQ ID NO: 1499, SEQ ID NO: 1506, SEQ ID NO: 1513, SEQ ID NO: 1514, SEQ ID NO: 1515, SEQ ID NO: 1516, SEQ ID NO: 1517, SEQ ID NO: 1524, SEQ ID NO: 1531, SEQ ID NO: 1538, SEQ ID NO: 1539, SEQ ID NO: 1540, SEQ ID NO: 1547, SEQ ID NO: 1554, SEQ ID NO: 1555, SEQ ID NO: 1556, SEQ ID NO: 1563, SEQ ID NO: 1570, SEQ ID NO: 1571, SEQ ID NO: 1572, SEQ ID NO: 1573, SEQ ID NO: 1574, SEQ ID NO: 1575, SEQ ID NO: 1576, SEQ ID NO: 1577, SEQ ID NO: 1578, SEQ ID NO: 1579, SEQ ID NO: 1580, SEQ ID NO: 1581, SEQ ID NO: 1789, SEQ ID NO: 1802, SEQ ID NO: 1815, SEQ ID NO: 1828, SEQ ID NO: 1841, SEQ ID NO: 1854, SEQ ID NO: 1867, SEQ ID NO: 1880, SEQ ID NO: 1893, SEQ ID NO: 2075, SEQ ID NO: 2088, SEQ ID NO: 2101, SEQ ID NO: 2114, SEQ ID NO: 2127, SEQ ID NO: 2140, SEQ ID NO: 2153, SEQ ID NO: 2166, SEQ ID NO: 2192, SEQ ID NO: 2205, i SEQ ID NO: 2218 do 2228.
9. Sekvenca nukleinske kiseline naznačena time što kodira konstrukt protutijela kako je definirano u bilo kojem od zahtjeva 1 do 8.
10. Vektor naznačen time što sadrži sekvencu nukleinske kiseline definiranu u zahtjevu 9.
11. Stanica domaćina naznačena time što je transformirana ili transficirana sa sekvencom nukleinske kiseline kako je definirano u zahtjevu 9 ili s vektorom definiranim u zahtjevu 10.
12. Postupak za proizvodnju konstrukta protutijela u skladu s bilo kojim od zahtjeva 1 do 8, naznačen time što navedeni postupak uključuje kultiviranje stanice domaćina kako je definirano u zahtjevu 11 pod uvjetima koji omogućuju ekspresiju konstrukta protutijela kako je definirano u bilo kojem od zahtjeva 1 do 8 i oporavak dobivenog konstrukta protutijela iz kulture.
13. Farmaceutski pripravak naznačen time što sadrži konstrukt protutijela prema bilo kojem od zahtjeva 1 do 8, ili proizveden u skladu s postupkom prema zahtjevu 12.
14. Konstrukt protutijela prema bilo kojem od zahtjeva 1 do 8, ili proizveden u skladu s postupkom prema zahtjevu 12 naznačen time što je za uporabu u prevenciji ili liječenju melanoma ili metastatskog melanoma.
15. Komplet koji sadrži konstrukt protutijela prema bilo kojem od zahtjeva 1 do 8, ili proizveden u skladu s postupkom prema zahtjevu 12, vektor kako je definiran u zahtjevu 10, i/ili stanicu domaćina kako je definirana u zahtjevu 11.
HRP20191983TT 2013-01-25 2019-10-31 Konstrukti protutijela za cdh19 i cd3 HRP20191983T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361756991P 2013-01-25 2013-01-25
US201361785147P 2013-03-14 2013-03-14
PCT/EP2014/051550 WO2014114800A1 (en) 2013-01-25 2014-01-27 Antibody constructs for cdh19 and cd3
EP14705293.0A EP2948477B1 (en) 2013-01-25 2014-01-27 Antibody constructs for cdh19 and cd3

Publications (1)

Publication Number Publication Date
HRP20191983T1 true HRP20191983T1 (hr) 2020-02-07

Family

ID=50137614

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20191983TT HRP20191983T1 (hr) 2013-01-25 2019-10-31 Konstrukti protutijela za cdh19 i cd3

Country Status (37)

Country Link
US (5) US20140322218A1 (hr)
EP (2) EP3699194B1 (hr)
JP (2) JP6522517B2 (hr)
KR (2) KR102230620B1 (hr)
CN (1) CN105121468B (hr)
AP (1) AP2015008608A0 (hr)
AU (2) AU2014209877B2 (hr)
BR (1) BR112015017548B1 (hr)
CA (1) CA2896372C (hr)
CL (1) CL2015002071A1 (hr)
CR (1) CR20150437A (hr)
CY (1) CY1123005T1 (hr)
DK (1) DK2948477T3 (hr)
EA (1) EA036950B1 (hr)
ES (2) ES2929276T3 (hr)
HK (1) HK1211946A1 (hr)
HR (1) HRP20191983T1 (hr)
HU (1) HUE046412T2 (hr)
IL (2) IL240092B (hr)
JO (1) JO3519B1 (hr)
LT (1) LT2948477T (hr)
MX (1) MX369149B (hr)
MY (1) MY175075A (hr)
NZ (1) NZ709318A (hr)
PE (1) PE20151613A1 (hr)
PH (1) PH12015501651B1 (hr)
PL (1) PL2948477T3 (hr)
PT (1) PT2948477T (hr)
RS (1) RS59633B1 (hr)
SG (2) SG10201705874QA (hr)
SI (1) SI2948477T1 (hr)
TN (1) TN2015000317A1 (hr)
TW (2) TWI695012B (hr)
UA (1) UA118749C2 (hr)
UY (1) UY35286A (hr)
WO (1) WO2014114800A1 (hr)
ZA (1) ZA201506129B (hr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010037835A2 (en) * 2008-10-01 2010-04-08 Micromet Ag Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
EP3375790A1 (en) * 2008-10-01 2018-09-19 Amgen Research (Munich) GmbH Cross-species-specific single domain bispecific single chain antibody
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
US9920121B2 (en) 2013-01-25 2018-03-20 Amgen Inc. Antibodies targeting CDH19 for melanoma
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
JP6749312B2 (ja) * 2014-07-31 2020-09-02 アムゲン リサーチ （ミュンヘン） ゲーエムベーハーＡＭＧＥＮ Ｒｅｓｅａｒｃｈ（Ｍｕｎｉｃｈ）ＧｍｂＨ 最適化された種間特異的二重特異性単鎖抗体コンストラクト
AR101400A1 (es) * 2014-07-31 2016-12-14 Amgen Res (Munich) Gmbh Constructo de anticuerpo de cadena individual biespecífico con distribución mejorada de tejido
UY36245A (es) * 2014-07-31 2016-01-29 Amgen Res Munich Gmbh Constructos de anticuerpos para cdh19 y cd3
ES2899779T3 (es) 2014-12-05 2022-03-14 Memorial Sloan Kettering Cancer Center Receptores antigénicos quiméricos dirigidos a receptor acoplado a proteína G y usos de los mismos
EP3227324A4 (en) 2014-12-05 2018-08-29 Memorial Sloan Kettering Cancer Center Antibodies targeting g-protein coupled receptor and methods of use
AU2016260909B2 (en) * 2015-05-13 2019-08-22 Ablynx N.V. T cell recruiting polypeptides based on CD3 reactivity
ES2889906T3 (es) 2015-05-21 2022-01-14 Harpoon Therapeutics Inc Proteínas de unión triespecíficas y usos médicos
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
WO2017023859A1 (en) * 2015-07-31 2017-02-09 Memorial Sloan-Kettering Cancer Center Antigen-binding proteins targeting cd56 and uses thereof
TWI793062B (zh) * 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
BR112018008904A2 (pt) 2015-11-03 2018-11-27 Janssen Biotech Inc anticorpos que se ligam especificamente a tim-3 e seus usos
CN113912725B (zh) * 2016-01-09 2024-03-08 嘉立医疗科技(广州)有限公司 用于癌症治疗的钙粘蛋白-17特异性抗体和细胞毒性细胞
CN109311979A (zh) 2016-02-03 2019-02-05 安进研发（慕尼黑）股份有限公司 Psma和cd3双特异性t细胞接合抗体构建体
EA039859B1 (ru) * 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
CN109641047A (zh) 2016-05-20 2019-04-16 哈普恩治疗公司 单结构域血清白蛋白结合蛋白质
SG11201810331YA (en) 2016-05-20 2018-12-28 Harpoon Therapeutics Inc Single chain variable fragment cd3 binding proteins
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
US10738115B2 (en) * 2016-07-06 2020-08-11 National Research Council Of Canada Humanized antibodies transmigrating the blood-brain barrier and uses thereof
MX2019006045A (es) 2016-11-23 2019-11-11 Harpoon Therapeutics Inc Proteinas triespecificas dirigidas a psma y metodos de uso.
EP3544997A4 (en) 2016-11-23 2020-07-01 Harpoon Therapeutics, Inc. PROSTATE SPECIFIC MEMBRANE ANTIGEN BINDING PROTEIN
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
CA3063362A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Msln targeting trispecific proteins and methods of use
JP7090347B2 (ja) 2017-05-12 2022-06-24 ハープーン セラピューティクス，インク． メソテリン結合タンパク質
CR20200195A (es) 2017-10-13 2020-08-14 Harpoon Therapeutics Inc Proteínas de unión a antigenos de maduraciòn de celulas b
KR102569133B1 (ko) 2017-10-13 2023-08-21 하푼 테라퓨틱스, 인크. 삼중특이적 단백질 및 사용 방법
EP3790904A1 (en) * 2018-05-08 2021-03-17 Amgen Inc. Bispecific antibodies with cleavable c-terminal charge-paired tags
CN113286817A (zh) 2018-09-25 2021-08-20 哈普恩治疗公司 Dll3结合蛋白及使用方法
GB201918230D0 (en) 2019-12-11 2020-01-22 Prec Therapeutics Ltd Antibodies and their uses
CN115768463A (zh) 2020-02-21 2023-03-07 哈普恩治疗公司 Flt3结合蛋白及使用方法
EP4146266A2 (en) * 2020-05-05 2023-03-15 University of Massachusetts Anti-sars-cov-2 spike protein antibodies and methods of use
AU2022227761A1 (en) * 2021-02-26 2023-09-28 Fred Hutchinson Cancer Center Protective antibodies against respiratory viral infections
IL310840A (en) * 2021-08-16 2024-04-01 Janssen Biotech Inc Anti-VEGFR1 antibodies and uses thereof
CN116554340A (zh) * 2022-01-28 2023-08-08 江苏众红生物工程创药研究院有限公司 新型长效化和高活性且更安全的抗体构建体
WO2023235805A2 (en) * 2022-06-01 2023-12-07 The Wistar Institute Of Anatomy And Biology Dna-encoded bispecific antibodies targeting carbonic anhydrase 9 and methods of use in cancer therapeutics

Family Cites Families (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US721367A (en) 1902-05-26 1903-02-24 Andrew J Gunter Bellows.
US3180193A (en) 1963-02-25 1965-04-27 Benedict David Machines for cutting lengths of strip material
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
ATE120761T1 (de) 1987-05-21 1995-04-15 Creative Biomolecules Inc Multifunktionelle proteine mit vorbestimmter zielsetzung.
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
EP0320015B1 (en) 1987-12-09 1994-07-20 Omron Tateisi Electronics Co. Inductive data communicating apparatus
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
JPH06506105A (ja) 1990-08-29 1994-07-14 ファーミング　ビーブイ 哺乳動物細胞における相同性組換え
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
CA2105984C (en) 1991-03-11 2002-11-26 Milton J. Cormier Cloning and expression of renilla luciferase
WO1992022670A1 (en) 1991-06-12 1992-12-23 Genpharm International, Inc. Early detection of transgenic embryos
WO1992022645A1 (en) 1991-06-14 1992-12-23 Genpharm International, Inc. Transgenic immunodeficient non-human animals
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
AU3328493A (en) 1991-12-17 1993-07-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
EP0648265A4 (en) 1992-06-18 1996-12-04 Genpharm Int PROCESS FOR THE PRODUCTION OF NON-HUMAN TRANSGENIC ANIMALS HAVING AN ARTIFICIAL YEAST CHROMOSOME.
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
CA2146559A1 (en) 1992-10-23 1994-05-11 Melanie K. Spriggs Methods of preparing soluble, oligomeric proteins
US5981175A (en) 1993-01-07 1999-11-09 Genpharm Internation, Inc. Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
KR960705209A (ko) 1993-09-10 1996-10-09 잭 엠. 그랜노위츠 녹색 형광 단백의 용도
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5777079A (en) 1994-11-10 1998-07-07 The Regents Of The University Of California Modified green fluorescent proteins
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5811524A (en) 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
EP0843961B1 (en) 1995-08-29 2007-01-24 Kirin Beer Kabushiki Kaisha Chimeric animal and method for constructing the same
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5804387A (en) 1996-02-01 1998-09-08 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
US5925558A (en) 1996-07-16 1999-07-20 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
JP3795533B2 (ja) 1996-12-12 2006-07-12 プロルーム・リミテツド 感染性物質を検出及び同定するための方法及び装置
EP1064360B1 (en) 1998-03-27 2008-03-05 Prolume, Ltd. Luciferases, gfp fluorescent proteins, their nucleic acids and the use thereof in diagnostics
TR200003087T2 (tr) 1998-04-21 2001-02-21 Micromet Ag Yeni CD19 X CD3 Spesifik polipeptidler ve kullanımları
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
AU2002348263B2 (en) 2001-11-30 2008-10-16 Amgen Fremont Inc. Transgenic animals bearing human IgLamda light chain genes
JP2006512895A (ja) * 2002-06-28 2006-04-20 ドマンティス リミテッド リガンド
EP1711632A4 (en) 2004-01-19 2009-03-11 Technion Res & Dev Foundation DIAGNOSTIC TEST FOR PARKINSON
WO2006007441A1 (en) * 2004-06-16 2006-01-19 Cardo Systems Inc. Wireless communication headset with microphone switching system
MX2007000387A (es) 2004-07-16 2007-03-28 Micromet Ag Polipeptidos de expresion mejorada.
DK1827492T3 (da) 2004-11-30 2010-11-22 Curagen Corp Antistoffer rettet mod GPNMB og anvendelser deraf
WO2006138181A2 (en) 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
MY169746A (en) 2005-08-19 2019-05-14 Abbvie Inc Dual variable domain immunoglobulin and uses thereof
JP5686953B2 (ja) 2005-10-11 2015-03-18 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー 交差種特異的（ｃｒｏｓｓ−ｓｐｅｃｉｅｓ−ｓｐｅｃｉｆｉｃ）抗体を含む組成物および該組成物の使用
US20070161019A1 (en) * 2005-11-04 2007-07-12 Johji Inazawa Method for detecting cancer and a method for suppressing cancer
EP2392672A1 (en) 2006-06-02 2011-12-07 GlaxoSmithKline Biologicals S.A. Method for identifying whether a patient will be responder or not to immunotherapy based on the differential expression of the CD52 gene
US8430938B1 (en) 2006-07-13 2013-04-30 The United States Of America As Represented By The Secretary Of The Navy Control algorithm for autothermal reformer
BRPI0809594A2 (pt) * 2007-04-03 2019-08-27 Micromet Ag polipeptídeo, seqüência de ácido nucléico, vetor, hospedeiro, processo para a produção de um polipeptídeo, composição farmacêutica, uso de um polipeptídeo, método para prevenção, tratamento ou melhora de uma doença, em um indivíduo com necessidade do mesmo, kit, método para a identificação de um polipeptídeo(s)
PL2520590T3 (pl) * 2007-04-03 2019-02-28 Amgen Research (Munich) Gmbh Domena wiążąca wykazująca krzyżową swoistość gatunkową
US8464584B2 (en) 2007-10-19 2013-06-18 Food Equipment Technologies Company, Inc. Beverage dispenser with level measuring apparatus and display
US20100310451A1 (en) 2007-11-01 2010-12-09 The Royal Institution For The Advancement Of Learn Altered n-cadherin processing in tumor cells by furin and proprotein convertase 5a (pc5a)
EP2072971A1 (en) 2007-12-17 2009-06-24 Services Pétroliers Schlumberger Variable throat venturi flow meter
WO2010037835A2 (en) * 2008-10-01 2010-04-08 Micromet Ag Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
CA3153682A1 (en) * 2008-11-17 2010-05-20 Veracyte, Inc. Methods and compositions of molecular profiling for disease diagnostics
US9676298B2 (en) 2010-12-30 2017-06-13 C. Rob. Hammerstein Gmbh & Co. Kg Longitudinal adjustment device for a motor vehicle seat, comprising two pairs of rails
US9243058B2 (en) 2012-12-07 2016-01-26 Amgen, Inc. BCMA antigen binding proteins
US9920121B2 (en) * 2013-01-25 2018-03-20 Amgen Inc. Antibodies targeting CDH19 for melanoma
JO3519B1 (ar) * 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
CA2903258C (en) * 2013-03-15 2019-11-26 Amgen Inc. Heterodimeric bispecific antibodies
WO2015103166A1 (en) * 2013-12-30 2015-07-09 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Prostate cancer gene profiles and methods of using the same
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof
JP6749312B2 (ja) 2014-07-31 2020-09-02 アムゲン リサーチ （ミュンヘン） ゲーエムベーハーＡＭＧＥＮ Ｒｅｓｅａｒｃｈ（Ｍｕｎｉｃｈ）ＧｍｂＨ 最適化された種間特異的二重特異性単鎖抗体コンストラクト
US10105142B2 (en) 2014-09-18 2018-10-23 Ethicon Llc Surgical stapler with plurality of cutting elements
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI793062B (zh) 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
CN109311979A (zh) 2016-02-03 2019-02-05 安进研发（慕尼黑）股份有限公司 Psma和cd3双特异性t细胞接合抗体构建体
EA039859B1 (ru) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
DK3411402T3 (da) 2016-02-03 2022-02-07 Amgen Res Munich Gmbh Bcma- og cd3-bispecifikke t-celle-engagerende antistofkonstruktioner
CN111315780A (zh) * 2017-12-11 2020-06-19 安进公司 双特异性抗体产品的连续制造工艺

Also Published As

Publication number Publication date
PH12015501651A1 (en) 2015-10-19
UY35286A (es) 2014-07-31
EP2948477A1 (en) 2015-12-02
HK1211946A1 (en) 2016-06-03
AU2014209877A1 (en) 2015-07-09
KR20150134322A (ko) 2015-12-01
TWI695012B (zh) 2020-06-01
KR102452351B1 (ko) 2022-10-07
CL2015002071A1 (es) 2016-06-10
US20150368343A1 (en) 2015-12-24
KR102230620B1 (ko) 2021-03-23
BR112015017548A2 (pt) 2017-07-11
US20200071405A1 (en) 2020-03-05
EP3699194A1 (en) 2020-08-26
US10059766B2 (en) 2018-08-28
CA2896372A1 (en) 2014-07-31
SI2948477T1 (sl) 2019-12-31
MX2015009594A (es) 2016-03-09
RS59633B1 (sr) 2020-01-31
TWI660971B (zh) 2019-06-01
BR112015017548B1 (pt) 2023-12-05
ZA201506129B (en) 2020-02-26
US20190016805A1 (en) 2019-01-17
PE20151613A1 (es) 2015-11-14
NZ709318A (en) 2020-12-18
PH12015501651B1 (en) 2015-10-19
TW201429991A (zh) 2014-08-01
IL275114B (en) 2022-04-01
MY175075A (en) 2020-06-04
JP2019165730A (ja) 2019-10-03
CN105121468A (zh) 2015-12-02
UA118749C2 (uk) 2019-03-11
IL275114A (en) 2020-07-30
EP2948477B1 (en) 2019-10-16
CY1123005T1 (el) 2021-10-29
AP2015008608A0 (en) 2015-07-31
PL2948477T3 (pl) 2020-03-31
KR20210038682A (ko) 2021-04-07
US11498964B2 (en) 2022-11-15
ES2759248T3 (es) 2020-05-08
AU2018203339A1 (en) 2018-06-14
CN105121468B (zh) 2020-11-10
TN2015000317A1 (en) 2017-01-03
CR20150437A (es) 2016-02-04
PT2948477T (pt) 2019-12-11
US20240010724A1 (en) 2024-01-11
IL240092B (en) 2020-06-30
IL240092A0 (en) 2015-09-24
ES2929276T3 (es) 2022-11-28
AU2014209877B2 (en) 2018-02-15
SG11201505232WA (en) 2015-08-28
CA2896372C (en) 2023-10-24
MX369149B (es) 2019-10-30
JO3519B1 (ar) 2020-07-05
JP6880100B2 (ja) 2021-06-02
EA201591376A1 (ru) 2015-12-30
EP3699194B1 (en) 2022-07-20
DK2948477T3 (da) 2020-01-06
EA036950B1 (ru) 2021-01-19
LT2948477T (lt) 2019-11-25
JP2016511750A (ja) 2016-04-21
TW201837055A (zh) 2018-10-16
US20140322218A1 (en) 2014-10-30
HUE046412T2 (hu) 2020-03-30
JP6522517B2 (ja) 2019-05-29
SG10201705874QA (en) 2017-08-30
BR112015017548A8 (pt) 2019-10-29
WO2014114800A1 (en) 2014-07-31

Similar Documents

Publication Publication Date Title
HRP20191983T1 (hr) Konstrukti protutijela za cdh19 i cd3
JP2016511750A5 (hr)
HRP20211073T1 (hr) Konstrukti bispecifičnih protutijela koji vežu dll3 i cd3
HRP20230401T1 (hr) Konstrukti protutijela za flt3 i cd3
HRP20191697T1 (hr) Vezujuće molekule za bcma i cd3
HRP20231410T1 (hr) Konstrukti bispecifičnih antitijela koji vežu mezotelin i cd3
IL256870B2 (en) Constructs for bispecific antibodies that bind to CD70 and CD3 and uses thereof
HRP20221141T1 (hr) Anti-lag3 protutijela
HRP20191704T1 (hr) Multispecifična protutijela
JP2017522892A5 (hr)
HRP20201993T1 (hr) Protutijela protiv pd-1
RU2019100481A (ru) Биспецифические антитела-ингибиторы контрольных точек
HRP20130883T4 (hr) Međuvrsno specifična cd3-epsilon-vežuća domena
HRP20201503T1 (hr) MOLEKULE SA SPECIFIČNOŠĆU ZA CD45 i CD79
HRP20190932T1 (hr) Molekule protutijela koje se vežu na il-17a i il-17f
HRP20120759T1 (hr) Bispecifična veziva specifična između vrsta
JP2013063981A5 (hr)
JP2019500862A5 (hr)
FI2155783T4 (fi) Lajien välisesti spesifinen cd3-epsilon-sitoutumisdomeeni
JP2020504101A5 (hr)
RU2019102008A (ru) Гетеродимерные антитела, которые связывают рецептор соматостатина 2-го типа
HRP20191608T1 (hr) Proteini s ponavljajućim dipeptidom kao terapeutsko ciljno mjesto kod neurodegenerativnih bolesti s ekspanzijom ponavljajućeg heksanukleotida
JP2019527047A5 (hr)
HRP20131167T1 (hr) Antitijela za humani receptor programirane smrti pd-1
JP2010022372A5 (hr)